Capella Biosciences Limited logo

Capella Biosciences Limited

Capella Biosciences is a virtual, discovery stage, start-up biopharma company developing novel medicines based on monoclonal antibodies (mAbs) for the treatment of oncology and autoimmune disease.

Capella Biosciences focuses on the employment of proprietary technologies to discover, develop, and commercialize medicines based on mAbs therapeutics independently, as well in collaboration with biotechnology and academic partners.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.capellabioscience.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
158-160 North Gower Street NW1 2ND
London
United Kingdom
Email
Contact Number
+44 77 4784 5906

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

In Mar 2016, Capella BioScience, raised £11 Mn (US$15.5 Mn) Series A financing provided by Advent Life Sciences, Medicxi Ventures and Osage University Partners.

In 2014, Capella BioScience raised £1.5 Mn of equity financing from Advent Life sciences and Index ventures.